Scarica l'app Stockscreener
60.04
0.47%
0.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Disc Medicine Inc Borsa (IRON) Ultime notizie
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm - lincolnjournal.com
Atlas Venture Life Science Advisors LLC Has $141.58 Million Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates - marketscreener.com
Disc Medicine, Inc. $IRON Stake Trimmed by Victory Capital Management Inc. - MarketBeat
Is Disc Medicine (IRON) Pricing Attractive After Recent Pullback And DCF Valuation Gap - simplywall.st
IRON Investors Lose Up to $22/Share — LEVI & KORSINSKY, LLP Investigates Disc Medicine - Morningstar
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals - Yahoo Finance
IRON: Phase III data for bitopertin and key pipeline readouts are expected by year-end - TradingView
Disc Medicine (IRON) Is Down 8.2% After Wider 2025 Loss and ESOP Shelf FilingHas The Bull Case Changed? - simplywall.st
Disc Medicine Stock Pre-Market (+9.8%): Sector Lift on J&J Hematology Approval - Trefis
Blue Owl Capital Holdings LP Sells 20,000 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine prices upsized securities offering to raise total $250M - MSN
Disc Medicine, Inc. $IRON Shares Acquired by Vanguard Group Inc. - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - FinancialContent
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - simplywall.st
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
After FDA setback, Disc Medicine pushes rare blood drugs with $791M cash - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
Jean Franchi sells 7,081 IRON shares under 10b5-1 (IRON) - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - The Motley Fool
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):